The limited treatment of choice for advanced melanoma is immune checkpoint blockade (ICB) and molecularly targeted therapies, such as CTLA-4, PD-1/PD-L1 inhibitors, and BRAF inhibitors due to melanoma's high level of heterogeneity and aggressiveness [3, 4]. Here, CTLA4 is linked to melanoma.